MedImmune FluMist review
Executive Summary
Dec. 17 meeting of FDA's Vaccines & Related Biological Products Advisory Committee on MedImmune's FluMist intranasal vaccine for prevention of influenza will be held at the Marriott in Bethesda, Md., at 8:30 a.m. The committee is expected to focus on safety in children under five (1"The Pink Sheet" Nov. 4, p. 13)...
You may also be interested in...
FluMist Initial Indication May Exclude Patients Under Age Five
The initial label for MedImmune/Wyeth's intranasal influenza vaccine FluMist might not include an indication for children under age five
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.